Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the European Congress on Obesity (ECO) in Malaga, Spain, reveal that the drug leads ...

A new study has found that the weight-loss drug tirzepatide can help people lose a significant amount of weight and keep it ...

It works by stimulating insulin release when blood sugar levels are high, slowing down digestion to prevent blood sugar spikes and reducing appetite. By targeting both GLP-1 and GIP receptors ...

Novo Nordisk's are known as GLP-1 receptor agonists, while Lilly's drugs are dual GIP/GLP-1 receptor agonists -- in both cases, they act on hormones involved in the digestion process, regulating ...